

**4 February 2021**

**Kromek Group plc**  
("Kromek" or the "Company")

**Issue of Equity and Total Voting Rights**

Kromek Group plc, a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces the issuance of 338,000 new ordinary shares (the "Options") in the Company as a result of the exercise of employee options during the period from 1 February 2019 to 17 July 2020. Following the exercise of the Options, the Company's issued share capital consists of 344,897,089 ordinary shares of 1p each. This figure (344,897,089) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Application has been made for a total of 2,008,000 new ordinary shares to be admitted to trading on AIM ("Admission"). This number is made up of the Options and a further 1,670,000 new ordinary shares resulting from the historic exercise of options that were not previously admitted to trading. It is expected that Admission will occur on 10 February 2021. Following Admission, the Company will have 344,897,089 ordinary shares in issue and admitted to trading on AIM.

**For further information, please contact:**

**Kromek Group plc**

Arnab Basu, CEO  
Paul Farquhar, CFO

+44 (0)1740 626 060

**Cenkos Securities plc (Nominated Adviser and Broker)**

Max Hartley (NOMAD)  
Julian Morse (Sales)

+44 (0)20 7397 8900

**Luther Pendragon Ltd (PR)**

Harry Chathli  
Claire Norbury  
Joe Quinlan

+44 (0)20 7618 9100